company background image
ALK

ALK-AbellóCPSE:ALK B Stock Report

Market Cap

kr.31.6b

7D

6.3%

1Y

33.6%

Updated

14 Oct, 2021

Data

Company Financials +
ALK B fundamental analysis
Snowflake Score
Valuation0/6
Future Growth4/6
Past Performance3/6
Financial Health6/6
Dividends0/6

ALK B Overview

ALK-Abelló A/S operates as an allergy solutions company in Europe, North America, and internationally.

ALK-Abelló Competitors

Price History & Performance

Summary of all time highs, changes and price drops for ALK-Abelló
Historical stock prices
Current Share Pricekr.2,882.00
52 Week Highkr.1,965.00
52 Week Lowkr.3,310.00
Beta0.33
1 Month Change-0.35%
3 Month Change-2.37%
1 Year Change33.55%
3 Year Change171.89%
5 Year Change218.10%
Change since IPO321.96%

Recent News & Updates

Sep 11
ALK-Abelló (CPH:ALK B) Has A Rock Solid Balance Sheet

ALK-Abelló (CPH:ALK B) Has A Rock Solid Balance Sheet

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...

Aug 21
Calculating The Fair Value Of ALK-Abelló A/S (CPH:ALK B)

Calculating The Fair Value Of ALK-Abelló A/S (CPH:ALK B)

Today we will run through one way of estimating the intrinsic value of ALK-Abelló A/S ( CPH:ALK B ) by taking the...

Shareholder Returns

ALK BDK PharmaceuticalsDK Market
7D6.3%0.6%0.6%
1Y33.6%14.6%21.4%

Return vs Industry: ALK B exceeded the Danish Pharmaceuticals industry which returned 11.5% over the past year.

Return vs Market: ALK B exceeded the Danish Market which returned 20% over the past year.

Price Volatility

Is ALK B's price volatile compared to industry and market?
ALK B volatility
ALK B Beta0.33
Industry Beta0.45
Market Beta1

Stable Share Price: ALK B is not significantly more volatile than the rest of Danish stocks over the past 3 months, typically moving +/- 5% a week.

Volatility Over Time: ALK B's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19232,469Carsten Hellmannhttps://www.alk.net

ALK-Abelló A/S operates as an allergy solutions company in Europe, North America, and internationally. The company offers allergy immunotherapy products in the form of injections, sublingual drops, and tablets for the treatment of various allergies, including house dust mite, grass, tree, ragweed, and Japanese cedar. Its products include GRAZAX, RAGWITEK, RAGWIZAX, MITICURE, ODACTRA, CEDARCURE, and ITULAZAX for the treatment of allergic rhinitis; and ACARIZAX for treating allergic rhinitis and allergic asthma.

ALK-Abelló Fundamentals Summary

How do ALK-Abelló's earnings and revenue compare to its market cap?
ALK B fundamental statistics
Market Capkr.31.63b
Earnings (TTM)kr.55.00m
Revenue (TTM)kr.3.65b

575.2x

P/E Ratio

8.7x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ALK B income statement (TTM)
Revenuekr.3.65b
Cost of Revenuekr.1.49b
Gross Profitkr.2.16b
Expenseskr.2.11b
Earningskr.55.00m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

Nov 11, 2021

Earnings per share (EPS)5.01
Gross Margin59.20%
Net Profit Margin1.51%
Debt/Equity Ratio16.8%

How did ALK B perform over the long term?

See historical performance and comparison

Valuation

Is ALK-Abelló undervalued compared to its fair value and its price relative to the market?

575.18x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: ALK B (DKK2882) is trading above our estimate of fair value (DKK2847.36)

Significantly Below Fair Value: ALK B is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: ALK B is poor value based on its PE Ratio (575.2x) compared to the European Pharmaceuticals industry average (25.8x).

PE vs Market: ALK B is poor value based on its PE Ratio (575.2x) compared to the Danish market (15.8x).


Price to Earnings Growth Ratio

PEG Ratio: ALK B is poor value based on its PEG Ratio (12.1x)


Price to Book Ratio

PB vs Industry: ALK B is overvalued based on its PB Ratio (9.7x) compared to the XE Pharmaceuticals industry average (3.4x).


Future Growth

How is ALK-Abelló forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?

47.7%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: ALK B's forecast earnings growth (47.7% per year) is above the savings rate (0.1%).

Earnings vs Market: ALK B's earnings (47.7% per year) are forecast to grow faster than the Danish market (8.9% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: ALK B's revenue (11.2% per year) is forecast to grow faster than the Danish market (7.4% per year).

High Growth Revenue: ALK B's revenue (11.2% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: ALK B's Return on Equity is forecast to be low in 3 years time (13.8%).


Past Performance

How has ALK-Abelló performed over the past 5 years?

-33.6%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: ALK B has a large one-off loss of DKK39.0M impacting its June 30 2021 financial results.

Growing Profit Margin: ALK B's current net profit margins (1.5%) are higher than last year (1.5%).


Past Earnings Growth Analysis

Earnings Trend: ALK B's earnings have declined by 33.6% per year over the past 5 years.

Accelerating Growth: ALK B's earnings growth over the past year (12.2%) exceeds its 5-year average (-33.6% per year).

Earnings vs Industry: ALK B earnings growth over the past year (12.2%) exceeded the Pharmaceuticals industry 10.2%.


Return on Equity

High ROE: ALK B's Return on Equity (1.7%) is considered low.


Financial Health

How is ALK-Abelló's financial position?


Financial Position Analysis

Short Term Liabilities: ALK B's short term assets (DKK2.3B) exceed its short term liabilities (DKK1.4B).

Long Term Liabilities: ALK B's short term assets (DKK2.3B) exceed its long term liabilities (DKK934.0M).


Debt to Equity History and Analysis

Debt Level: ALK B's debt to equity ratio (16.8%) is considered satisfactory.

Reducing Debt: ALK B's debt to equity ratio has reduced from 22.3% to 16.8% over the past 5 years.

Debt Coverage: ALK B's debt is well covered by operating cash flow (65.4%).

Interest Coverage: ALK B earns more interest than it pays, so coverage of interest payments is not a concern.


Balance Sheet


Dividend

What is ALK-Abelló current dividend yield, its reliability and sustainability?

0.22%

Forecast Dividend Yield


Dividend Yield vs Market

Notable Dividend: Unable to evaluate ALK B's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ALK B's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ALK B's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ALK B's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: ALK B is not paying a notable dividend for the Danish market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ALK B's dividend in 3 years as they are not forecast to pay a notable one for the Danish market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.6yrs

Average management tenure


CEO

Carsten Hellmann (57 yo)

5.42yrs

Tenure

Mr. Carsten Hellmann has been the Chief Executive Officer and President at ALK-Abelló A/S since May 17, 2016. Mr. Hellmann serves as the Chief Executive Officer at Merial Inc., Boehringer Ingelheim Animal...


Leadership Team

Experienced Management: ALK B's management team is considered experienced (4.6 years average tenure).


Board Members

Experienced Board: ALK B's board of directors are not considered experienced ( 2.6 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

ALK-Abelló A/S's employee growth, exchange listings and data sources


Key Information

  • Name: ALK-Abelló A/S
  • Ticker: ALK B
  • Exchange: CPSE
  • Founded: 1923
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: kr.31.635b
  • Shares outstanding: 10.98m
  • Website: https://www.alk.net

Number of Employees


Location

  • ALK-Abelló A/S
  • Boge Alle 6-8
  • Horsholm
  • Capital Region of Denmark
  • 2970
  • Denmark

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/10/14 21:21
End of Day Share Price2021/10/14 00:00
Earnings2021/06/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.